Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Study Reaffirms Safety and Efficacy Profile of Pradaxa

By Drug Discovery Trends Editor | November 4, 2014

A U.S. Food and Drug Administration (FDA) study of more than 134,000 Medicare patients found that Pradaxa was associated with significantly reduced risks of ischemic stroke, intracranial hemorrhage and death, and a significantly increased risk of major gastrointestinal hemorrhage, compared with warfarin in patients with non-valvular atrial fibrillation (NVAF).The study found no difference in major bleeds or myocardial infarction with Pradaxa compared to warfarin. The study, which was published online in Circulation, further reinforces the favorable benefit/risk profile of Pradaxa, as shown in the pivotal RE-LY trial for stroke risk reduction in NVAF.

“This is the largest and most rigorous post-marketing study of Pradaxa in routine clinical practice and supports the positive risk/benefit profile of Pradaxa,” said Sabine Luik, MD, senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals Inc. “Patient safety is of utmost importance and we are pleased to see these findings further support the value of Pradaxa a treatment option for NVAF patients”.

The FDA study is based on data from elderly patients older than 65 years enrolled in Medicare who started therapy with Pradaxa or warfarin between October 2010 and December 2012. Each group comprised 67,207 patients. The analysis showed that Pradaxa was generally associated with better patient outcomes compared to warfarin. The primary outcomes were:

•20% reduced risk of ischemic stroke.

•No difference in major hemorrhage.

•66% reduced risk of intracranial hemorrhage.

•28% increased risk of gastrointestinal bleeding.

•No difference in acute myocardial infarction.

The study also found the following secondary outcomes:

•14% reduced risk of mortality.

•No difference in all hospitalized bleeds.

The FDA had announced initial findings of their analysis in a Drug Safety Communication on its website in May 2014, stating that “As a result of our latest findings, we still consider Pradaxa to have a favorable benefit to risk profile and have made no changes to the current label or recommendations for use.” This study was performed as part of the SafeRx Project, a joint initiative of the Centers for Medicare & Medicaid Services (CMS) and the FDA.

Date: November 4, 2014

Source: PR Newswire


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE